Trial Profile
A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Capecitabine
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms ARISTOTLE
- 03 Oct 2023 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 15 Jan 2018 Planned End Date changed from 25 Oct 2022 to 29 Dec 2023.